Tacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis

Authors

  • Rashmi Kumari Senior resident, RIO, IGIMS Patna
  • Bhawesh Chandra Saha Senior resident AIIMS Patna
  • Bibhuti Prasanna Sinha Additional Professor, HOD, RIO, IGIMS ,Patna
  • Nilesh Mohan Associate Professor, RIO, IGIMS, Patna

DOI:

https://doi.org/10.3126/nepjoph.v9i2.19257

Keywords:

VKC, TOSS, TSSS

Abstract

Introduction: The aim of the study was to evaluate and compare the efficacy, side effects and recurrence rate of vernal kerato conjunctivitis (VKC) with 0.03% tacrolimus and 0.05% cyclosporin.

Material and method: A prospective randomised double blinded comparative study was conducted at a tertiary eye center. 46 Patients of VKC between March 2015- August 2015 were randomly divided into two groups and treated for 6weeks with either Tacrolimus(0.03%) eye ointment BD or Cyclosporine (0.05%) eyedrops QID.The main outcome measures were scoring and comparison of Total subjective symptom scores (TSSS) and Total objective ocular sign scores (TOSS) within and between the Groups at each follow up.Thirty two patients, sixteen from each group, with comparable baseline characters were analysed.

Results: With treatment both TSSS and TOSS decreased consistently in both groups without any adverse effects but an increase in scores was noticed within two weeks after drug withdrawal.

Conclusion: Both drugs are equally effective and safe in VKC but with short lasting effect.

Downloads

Download data is not yet available.
Abstract
1479
PDF
1510

Downloads

Published

2018-02-21

How to Cite

Kumari, R., Saha, B. C., Sinha, B. P., & Mohan, N. (2018). Tacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis. Nepalese Journal of Ophthalmology, 9(2), 128–135. https://doi.org/10.3126/nepjoph.v9i2.19257

Issue

Vol. 9 No. 2 (2017)

Section

Original Articles

License

This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.